We found that high expression of ANXA2 predicted malignant pathological subtypes of glioma and poor patient prognosis, and that ANXA2 expression was closely related to the glioma-related immune response, especially inflammatory activity and immunosuppression. The gene discussed is ANXA2; the disease is central nervous system cancer.